Silica nanoparticles for drug loading in 2026: overview
Silica nanoparticles are carriers that load therapeutic molecules, transport them and release them at a target or over time. Mesoporous structures offer internal pore space for drug cargo, while surface chemistry can help control dispersibility, targeting and release. The field matters because many drug candidates have poor solubility or limited delivery to specific tissues. The main technical challenge is balancing reliable loading and release with carrier degradation, safety and predictable behavior in the body.
Recent work is moving toward responsive and targeted delivery alongside better ways to observe where carriers go. In September 2026, researchers at the University of Valencia and Polytechnic University of Valencia reported paclitaxel delivery with coumarin imaging for hypoxic tumors, and label-free X-ray fluorescence tracking of core-shell particles in vivo. Other September 2026 studies explored pH- and redox-responsive doxorubicin carriers for ovarian cancer, and chitosan microspheres containing doxorubicin-loaded silica nanoparticles for postoperative osteosarcoma management. These designs address delivery control and monitoring, but consistent in vivo tracking and translation beyond laboratory studies remain important hurdles.
- 1Control release locally: Stimuli-responsive release is gaining momentum as researchers use pH, redox conditions and enzymes to trigger drug release near diseased tissue.
- 2Pair delivery with imaging: Theranostic designs that combine drug delivery and imaging, such as the September 2026 hypoxic-tumor study, address the need to track both cargo and carrier behavior.
- 3Translation remains difficult: In vivo tracking and control of carrier degradation remain central bottlenecks between promising silica formulations and predictable therapeutic performance.
Top organizations working on silica nanoparticles for drug loading
Ranked by Linknovate activity score · last 24 monthsThe activity score adds up the relevance of every patent, publication, grant and news item linking an organization to silica nanoparticles for drug loading. Showing 7 of 1,353 organizations.
| # | Organization | Approach | Signals (24 mo) | Momentum | Why it matters |
|---|---|---|---|---|---|
| 1 | 
Chinese Academy of Sciences CAS
Research · China |
Surface functionalization and targeting | PUB 60 | -12% | Research includes ligand-modified nanoparticle delivery and PEG-coated silica carriers loaded with nicorandil, addressing targeted transport and delivery of therapeutic compounds. |
| 2 | 
Central South University
Research · China |
Stimuli-responsive release | PUB 26 | +89% | Investigates mesoporous silica carriers for drug delivery, including iron-doped particles for combined chemotherapy and chemodynamic therapy; recent work examined how particle size affects cellular metabolism. |
| 3 | 
Fudan University
Research · China |
Stimuli-responsive release | PUB 38 | -42% | Develops photothermal and pH-responsive mesoporous silica nanoparticles for controlled tumor-cell drug delivery, alongside metal-doped silica particles incorporated into injectable hydrogels. |
| 4 | 
University of Valencia
Research · Spain |
Stimuli-responsive release | PAT 1 · PUB 25 | +171% | Recently, researchers reported silica nanoparticles for simultaneous paclitaxel delivery and coumarin imaging in hypoxic tumors, and used label-free X-ray fluorescence to track core-shell particles in vivo. |
| 5 | 
National Institute of Pharmaceutical Education and Research
Research · India |
Mesoporous carriers | PUB 16 | -22% | Studies drug loading in mesoporous silica nanoparticles, including etodolac and quercetin, and develops injectable MSN-based hydrogels for sustained delivery of ibuprofen and resveratrol. |
| 6 | 
Sun Yat Sen University
Research · China |
Mesoporous carriers | PUB 32 | +67% | Recently, researchers incorporated doxorubicin-loaded mesoporous silica nanoparticles into chitosan microspheres for a postoperative osteosarcoma treatment platform; other work explores silica-based delivery for tissue repair. |
| 7 | 
Polytechnic University of Valencia
Research · Spain |
Stimuli-responsive release | PAT 1 · PUB 20 | +150% | Recently, researchers reported theranostic silica nanoparticles for selective paclitaxel delivery and imaging in hypoxic tumors, and tracked core-shell mesoporous particles in vivo using label-free X-ray fluorescence. |
| 8 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 9 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 10 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
Leading research centers
Leading research institutions 1,245 total
- Chinese Academy of Sciences CASChinaResearch includes ligand-modified nanoparticle delivery and PEG-coated silica carriers loaded with nicorandil, addressing targeted transport and delivery of therapeutic compounds.
- Central South UniversityChinaInvestigates mesoporous silica carriers for drug delivery, including iron-doped particles for combined chemotherapy and chemodynamic therapy; recent work examined how particle size affects cellular metabolism.
- University of ValenciaSpainRecently, researchers reported silica nanoparticles for simultaneous paclitaxel delivery and coumarin imaging in hypoxic tumors, and used label-free X-ray fluorescence to track core-shell particles in vivo.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
Where silica nanoparticles for drug loading innovation happens
Share of documents with at least one organization from each country.
Open the interactive map with all 1,353 organizationsMain technical approaches
Last 24 months| Approach | What it is | Documents | Leading organizations |
|---|---|---|---|
| Mesoporous carriers | Porous silica provides internal space for drug loading and adjustable release, but performance depends on pore design, cargo compatibility and carrier stability. | 2,714 |
University of Valencia, University of Tehran, Shenyang Pharmaceutical University |
| Hollow and core-shell architectures | Hollow or layered structures separate cargo from the surrounding environment and can support staged delivery, but add design and characterization complexity. | 172 |
Arba Minch University, Mashhad University of Medical Sciences, Bahauddin Zakariya University |
| Surface functionalization and targeting | Surface coatings and ligands can improve dispersion or direct carriers toward selected cells, but added chemistry can affect loading, safety and reproducibility. | 239 |
Taipei Medical University, National Institute of Pharmaceutical Education and Research, Nanjing Medical University |
| Stimuli-responsive release | Responsive gates release cargo when exposed to cues such as pH or redox conditions, but trigger specificity and behavior in living tissue can be difficult to control. | 578 |
Tehran University of Medical Sciences, Isfahan University of Technology, Islamic Azad University |
| Biodegradable silica carriers | Degradable designs aim to reduce long-term carrier persistence, but must preserve useful loading and release while breaking down predictably. | 658 |
Qingdao University, Shandong University, Parul University |
Emerging trends
Last 12 months vs previous 36 monthsTerms whose frequency in the last 12 months grew the most compared with the previous 36 months.
Funding and investment
Recent funding rounds
Recorded funding includes $8,788,294 across 15 grants since 2020 and $598,653,585 across 11 funding rounds. The listed round records are not necessarily specific to silica drug loading, so they should be treated as broader funding signals rather than confirmed investment in this technology.
Patent landscape
Top patent holders · last 24 monthsRecent developments
Latest news, duplicates removed- Oct 2026By combining a natural polymer with therapeutic ions, porous silica carriers, and magnetic nanoparticles, researchers outline how one adaptable dressing could target several biological problems that make diabetic wounds…AZoNano.com - Nanotechnology News Feed
- Oct 2026Newswise — The human body possesses the fascinating ability to heal itself. To do so, it replaces millions of old cells with new ones every day. However, some diseases can hinder these healing mechanisms – such as…Newswise Feature Channel: Dermatology
- Aug 2026A wearable patch that can detect fentanyl and automatically release naloxone may offer a new way to prevent unwitnessed opioid overdose deaths. A device smaller than a penny is designed to recognize dangerous fentanyl…SciTechDaily
- Aug 2026Life Sciences Research Jobs at JNU JNU life science jobs offer a rare opportunity for professionals in life sciences research at Jawaharlal Nehru University. The recruitment is for the role of Project Research…BioTecNika
- Month 20XXHidden developmentAvailable to registered users with alerts enabled.
Frequently asked questions about silica nanoparticles for drug loading
Which universities and research centers lead silica nanoparticles for drug loading research?
The Chinese Academy of Sciences CAS leads the listed recent research activity with 60 documents, followed by Fudan University with 38 and Sun Yat Sen University with 32. Other active groups include Central South University and the University of Valencia, each with 26. Their work spans targeted carriers, responsive release, tumor delivery and in vivo particle tracking.
How much funding has silica nanoparticles for drug loading received?
Recorded funding totals include $8,788,294 across 15 grants since 2020 and $598,653,585 across 11 funding rounds. These figures describe funding records associated with the topic data, but the listed round entries are not all clearly specific to silica drug loading. Treat the rounds total as a broader signal, not a confirmed investment total for silica-carrier development.
Who holds the most silica nanoparticles for drug loading patents?
Red Mountain Med Spa LLC is the largest named patent holder, with 3 patents. Oregon Health And Science University, Pdx Pharmaceuticals, LLC, and Yubeck, Inc. each have 2. The holder list also includes Harvard University, the University of Toronto, Carnegie Mellon University and Polytechnic University of Valencia, each with 1.
Is silica nanoparticles for drug loading patent activity growing?
Patent activity is down: the 24-month window records 39 patents, and the reported growth rate is -50.0%. That contrasts with the large publication base, indicating sustained research activity alongside a weaker recent patent trend. Patent counts alone do not establish commercial readiness or the technical value of the inventions.
How mature is silica nanoparticles for drug loading?
The field is research-intensive but has limited clinical evidence in the recorded data: it includes 13,056 publications, 274 patents and 3 clinical trials. Work is advancing through targeted, responsive and theranostic formulations, but these counts suggest that much activity remains preclinical or developmental. Translation also depends on demonstrating safety, predictable degradation and reliable performance in vivo.
What are the latest developments in silica nanoparticles for drug loading?
In September 2026, the University of Valencia and Polytechnic University of Valencia reported silica nanoparticles for paclitaxel delivery with coumarin imaging in hypoxic tumors, and label-free X-ray fluorescence tracking of core-shell particles in vivo. Other September 2026 work tested pH- and redox-responsive doxorubicin carriers and chitosan microspheres incorporating drug-loaded silica nanoparticles for postoperative osteosarcoma management.
What are the main approaches in silica nanoparticles for drug loading and how do they differ?
The main approaches are mesoporous carriers, hollow and core-shell architectures, surface functionalization and targeting, stimuli-responsive release, and biodegradable silica carriers. Mesoporous designs focus on pore-based loading; hollow and core-shell structures add spatial separation; surface modifications influence targeting; responsive systems use local cues to trigger release; and biodegradable designs aim to limit persistence. Each approach trades added control for more complex design and validation.
Which countries lead silica nanoparticles for drug loading?
China leads with 6,277 documents, or 45.4% of the recorded activity, followed by the United States with 1,990 documents and India with 1,255. Iran and Spain are also prominent, with 831 and 670 documents respectively. The country distribution indicates a strong research concentration in China, with significant activity across several other regions.
What are the applications of silica nanoparticles for drug loading?
Cancer therapy is the largest listed application, with 731 documents. Other application areas include oral delivery of poorly soluble drugs, with 394 documents; antimicrobial delivery, with 212; wound care and tissue repair, with 148; and central nervous system delivery, with 101. Recent studies also explore localized delivery and imaging-enabled tumor treatment.